drugset
drugset / Trial / NCT00796835

A Dose-proportionality Study of Five Tablet Strengths of ER OROS Paliperidone

NCT00796835 ↗

Phase 1 Completed 50 enrolled Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the dose proportionality of the 3-, 6-, 9-, 12-, and 15-mg tablets of ER OROS paliperidone. Additionally, the safety and tolerability of the treatments in healthy volunteers will be assessed.

Timeline

Start
2004-07
Primary completion
—
Completion
2004-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Paliperidone Unknown 3 mg Oral
Subject Paliperidone Unknown 6 mg Oral
Subject Paliperidone Unknown 9 mg Oral
Subject Paliperidone Unknown 12 mg Oral
Subject Paliperidone Unknown 15 mg Oral

Indications

schizophrenia